Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Price to Book Ratio (P/B) on January 14, 2025

Anebulo Pharmaceuticals, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Anebulo Pharmaceuticals, Inc. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Anebulo Pharmaceuticals, Inc. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Anebulo Pharmaceuticals, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO	Mr. Richard Anthony Cunningham
IPO Date	May 7, 2021
Location	United States
Headquarters	1415 Ranch Road 620 South
Employees	2
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Key trends

Past 5 years